Topography-dependent Prognostic Value of CDK5 in Cetuximab-Treated, RAS/BRAF-wild-type Metastatic Colorectal Cancer: A Retrospective Tissue-Microarray Analysis
Cancer Control · 2026-05 · 33
DOI: 10.1177/10732748261453119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Control, online erschienen am 15.05.2026. Verfasst von Qinghua Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Cetuximab, Cyclin-Dependent Kinase 5, Adenocarcinoma. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Jinhua Science and Technology Program.
Abstract (Originalsprache)
Introduction
The prognostic value of cyclin-dependent kinase 5 (CDK5) was investigated in a cohort of patients with cetuximab-treated, chemotherapy-refractory, dual wild-type Rat Sarcoma and v-raf murine sarcoma viral oncogene homolog B1 (RAS/BRAF) metastatic colorectal adenocarcinoma.
Methods
Immunohistochemistry (IHC) was used to retrospectively analyze the expression of CDK5 in metastatic colorectal adenocarcinoma tissue samples of 129 patients. All statistical computations were performed in R 4.0.5. Dichotomous clinicopathological variables were then cross-tabulated across CDK5 strata and compared with Pearson’s χ 2 test. Cumulative survival probabilities were estimated via the Kaplan–Meier estimator and contrasted with the log-rank test. Independent prognostic determinants were ascertained through Cox proportional-hazards.
Results
79 men and 50 women were enrolled in this study, with a median age 62.8 years. Among 129 specimens subjected to CDK5 IHC, 111 tumor cores yielded unequivocally evaluable results. 69 lesions were allocated to the low-to-intermediate expression tier (scores 0–2+), whereas 42 exhibited marked overexpression (score 3+). Elevated CDK5 immunoreactivity was shown to predict inferior progression-free survival (PFS) (7.0 versus 9.0 months; P =0.049) and a shortened cancer-specific survival (CSS) (27.8 vs 38.5 months; P =0.048). In addition, low-to-intermediate CDK5 expression remained independently associated with PFS (HR 0.544; 95 % CI 0.369–0.801; P =0.002) and CSS (HR 0.502; 95% CI: 0.329–0.766; P =0.001). CDK5 overexpression conferred a statistically significant detriment to PFS among patients harboring only extra-hepatic metastases ( P =0.012), while within the hepatic-metastatic subset, no survival discrepancy was discernible between the high and low-to-intermediate expression cohorts ( P =0.800).
Conclusions
Independent multivariable modelling identified elevated CDK5 as a robust predictor of both curtailed PFS and CSS. Intriguingly, this prognostic power appears to be contingent upon the site of disease: once the cancer metastasizes to the liver, the predictive signal of elevated CDK5 is abruptly extinguished.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Medical Oncology, The Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
- Department of Pathology, The Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, China.
- Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Chinese National Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Zhejiang Provincial Clinical Research Center for CANCER, Hangzhou, Zhejiang, China.
- Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China.
ORCID-Profile: Qinghua Wang, Jianfei Fu
Förderung
- the Jinhua Science and Technology Program
Zitieren
APA
Wang, Q., Zheng, H., Zheng, Z., Hu, B., Jiang, B., Fu, J., & Yuan, Y. (2026). Topography-dependent Prognostic Value of CDK5 in Cetuximab-Treated, RAS/BRAF-wild-type Metastatic Colorectal Cancer: A Retrospective Tissue-Microarray Analysis. Cancer Control, 33. https://doi.org/10.1177/10732748261453119
Vancouver
Wang Q, Zheng H, Zheng Z, Hu B, Jiang B, Fu J, et al. Topography-dependent Prognostic Value of CDK5 in Cetuximab-Treated, RAS/BRAF-wild-type Metastatic Colorectal Cancer: A Retrospective Tissue-Microarray Analysis. Cancer Control. 2026;33. doi:10.1177/10732748261453119
BibTeX
@article{Wang2026,
author = {Wang, Qinghua and Zheng, Hongjuan and Zheng, Zhijian and Hu, Bin and Jiang, Bingjing and Fu, Jianfei and Yuan, Ying},
title = {Topography-dependent Prognostic Value of CDK5 in Cetuximab-Treated, RAS/BRAF-wild-type Metastatic Colorectal Cancer: A Retrospective Tissue-Microarray Analysis},
journal = {Cancer Control},
year = {2026},
volume = {33},
doi = {10.1177/10732748261453119}
}
EUVIMED